Reta-Pep 10mg

Manufacturer: Dragon Pharma

Substance: R3tatrutide

Package: 1 vial (10 mg) (powder form)

$57.00

$48.45 Save 15%

Quantity:

Description
Reviews (0)

Dragon Pharma Reta-Pep

Dragon Pharma Reta-Pep10mg is a research-grade GIP/GLP-1/glucagon receptor triagonist provided as a lyophilized powder for investigators studying multi-receptor metabolic signaling, adipose biology, and energy-regulation pathways. Supplied in a 2 mL vial for customizable reconstitution and experimental dosing.

Overview: What is Reta-Pep?

Reta-Pep(LY3437943) is a synthetic triagonist engineered to activate three relevant metabolic receptors simultaneously:

GIPR — glucose-dependent insulinotropic polypeptide receptor
GLP-1R — glucagon-like peptide-1 receptor
GCGR — glucagon receptor

This multi-target profile makes Reta-Pep a valuable research tool for exploring cross-talk between incretin and glucagon systems, adipose tissue responsiveness, and systemic metabolic adaptations in preclinical models.

Mechanistic Profile

Reta-Pep triagonist activity enables the study of interconnected metabolic responses across multiple hormonal axes:

1. GIP Receptor Activation

Adipocyte signaling and nutrient partitioning
Energy-homeostasis research

2. GLP-1 Receptor Interaction

Satiety-related neural pathways and insulinotropic mechanisms
Gastrointestinal peptide responses

3. Glucagon Receptor Activity

Energy-expenditure models
Hepatic glucose output and lipid-oxidation studies
Cellular fuel-utilization pathways

Together these activities allow investigators to assess synergistic metabolic effects not replicable by single-pathway agonists alone.

Dose Escalation Timeline

Clear stages, weeks, doses and short plain-language expectations.

Starting Dose

Weeks 1–4 · Dose: 1–2 mg

Your body adapts to the medication. Mild nausea may occur but usually improves quickly.

Early Escalation

Weeks 5–8 · Dose: 4 mg

Weight loss becomes more noticeable and appetite suppression increases.

Middle Escalation

Weeks 9–12 · Dose: 6 mg

Continued progress; side effects typically stabilize.

Late Escalation

Weeks 13–16 · Dose: 8 mg

Approaching maintenance dose; significant weight loss is often visible.

Maintenance

Week 17+ · Dose: 8–12 mg

Target dose is individualized based on response and tolerability.

What Results Can You Expect?

Weekly Dose	Mean Loss @ 24 wks	Mean Loss @ 48 wks	% Achieving ≥15% Loss
1 mg	−7.2%	−8.7%	13%
4 mg	−13.1%	−17.3%	60%
8 mg	−15.9%	−22.8%	77%
12 mg	−17.5%	−24.2%	83%

Notes: "Mean Loss" shows average percentage weight change relative to baseline at the listed timepoints.

How to Use & Reconstitution

Form: Lyophilized powder supplied in a 2 mL vial.
Reconstitution: Reconstitute under aseptic conditions using sterile or bacteriostatic water to reach the concentration required for your protocol. Mix gently to dissolve; avoid vigorous agitation.
Aliquoting: After reconstitution, aliquot into single-use volumes to prevent repeated freeze-thaw cycles and maintain peptide integrity.
Application: Choose concentrations, exposure times and delivery routes appropriate to your in vitro or in vivo model. Run dose–response experiments to determine potency and effect windows for your specific assay.

Benefits of Reta-Pep by Dragon Pharma

In controlled preclinical studies and model systems, Dragon Pharma Reta-Pep has been investigated for effects such as:

Modulation of adipose signaling and lipid metabolism
Alterations in energy-expenditure pathways and substrate utilization
Changes in feeding-related neural circuits and nutrient handling
Influence on cellular and systemic glucose-regulatory mechanisms

Reta-Pep Side Effects

Depending on model and dose, research reports may note transient effects used to characterize pharmacology, including:

Gastrointestinal responses (e.g., transient motility changes)
Reduced food intake in behavioral models
Fluctuations in glucose or lipid markers
Mild reductions in activity or stress-related behaviors in some animal studies

Documenting and reporting these observations is essential for characterizing safety and mechanism in preclinical work.

Storage & Stability

Form: Lyophilized powder for maximum stability.

Short-term storage: Refrigerate at 2–8 °C.
Long-term storage: Store at −80 °C for extended preservation.
Handling: Avoid freeze–thaw cycles; aliquot for experimental use. Protect from light, air, and moisture.
Reconstitution: Commonly involves bacteriostatic water to achieve desired study concentrations.
Solution stability: Use sterile buffers (pH 5–6). Store reconstituted solutions at 4 °C for up to 30 days; freeze aliquots for longer storage.

For research purposes only.